{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T05:15:38Z","timestamp":1734153338869,"version":"3.30.2"},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,7,18]],"date-time":"2003-07-18T00:00:00Z","timestamp":1058486400000},"content-version":"vor","delay-in-days":47,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2003,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A colloidal dispersion formulation of 9\u2010aminocamptothecin (9\u2010AC) was administered intravenously to 10 dogs with previously untreated, spontaneously occurring, multicentric lymphoma. The dogs received a 72\u2010h infusion of 9\u2010AC at a rate of 46.5\u201351.25\u2003\u00b5g\u2003m<jats:sup>\u22122<\/jats:sup>\u2003h<jats:sup>\u22121<\/jats:sup>(total dose range 3.35\u20133.69\u2003mg\u2003m<jats:sup>\u22122<\/jats:sup>). This dose range was associated with myelosuppression, consisting principally of neutropenia with a nadir at 7 days following the start of infusion. Neutropenia and thrombocytopenia were the most common toxicoses and are most likely to be dose\u2010limiting toxicities; low\u2010grade gastrointestinal signs were rarely seen. Concentrations of 9\u2010AC lactone, as well as clinical toxicities, compare favourably with those found in humans. Tumour responses were seen in all treated dogs. Response to other chemotherapy, following cessation of 9\u2010AC treatment, was not obviously compromised even in dogs clinically resistant to 9\u2010AC. 9\u2010AC is a novel treatment drug for canine lymphoma, which appears to show great promise.<\/jats:p>","DOI":"10.1046\/j.1476-5829.2003.00012.x","type":"journal-article","created":{"date-parts":[[2003,7,18]],"date-time":"2003-07-18T14:49:42Z","timestamp":1058539782000},"page":"86-93","source":"Crossref","is-referenced-by-count":1,"title":["Intravenous administration of 9\u2010aminocamptothecin to dogs with lymphoma"],"prefix":"10.1111","volume":"1","author":[{"given":"A. S.","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Imondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. L.","family":"De Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,7,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2460\/ajvr.1994.55.11.1587","article-title":"Comparison of body surface area\u2010based and weight\u2010based dosage protocols for doxorubicin administration in dogs","volume":"55","author":"Arrington K.A.","year":"1994","journal-title":"American Journal of Veterinary Research"},{"key":"e_1_2_6_3_1","first-page":"317","article-title":"Phase\u2010I trial of the colloidal dispersion formulation of 9\u2010amino\u201020(S)\u2010camptothecin administered as a 72\u2010hour continuous intravenous infusion","volume":"4","author":"Eder J.P.","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050600"},{"key":"e_1_2_6_5_1","first-page":"641","article-title":"Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins","volume":"8","author":"Garcia\u2010Carbonero R.","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2555920"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050682"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00208a002"},{"key":"e_1_2_6_9_1","first-page":"228","volume-title":"Managing the Veterinary Cancer Patient","author":"Moore A.S.","year":"1995"},{"key":"e_1_2_6_10_1","first-page":"1399","article-title":"Evaluation of cisplatin induced emesis in dogs with malignant neoplasia: 115 cases (1984\u20131987)","volume":"195","author":"Ogilvie G.K.","year":"1989","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_6_11_1","first-page":"46","volume-title":"TNM Classification of Tumors in Domestic Animals","author":"Owen L.","year":"1980"},{"key":"e_1_2_6_12_1","first-page":"3573","article-title":"Resistance of human leukemic and normal lymphocytes to drug\u2010induced DNA cleavage and low levels of DNA topoisomerase II","volume":"48","author":"Potmesil M.","year":"1988","journal-title":"Cancer Research"},{"key":"e_1_2_6_13_1","first-page":"287","article-title":"9\u2010Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer","volume":"3","author":"De Souza P.L.","year":"1997","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_14_1","first-page":"432","article-title":"Relationship between the schedule dependence 9\u2010amino\u201020(S)\u2010camptothecin antitumor activity in mice and its plasma pharmacokinetics","volume":"33","author":"Supko J.G.","year":"1992","journal-title":"Proceedings of the American Association of Cancer Research"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(94)00051-4"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.11.836"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2345"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1476-5829.2003.00012.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1476-5829.2003.00012.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T06:32:18Z","timestamp":1734071538000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1476-5829.2003.00012.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.1046\/j.1476-5829.2003.00012.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1476-5829.2003.00012.x","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"type":"print","value":"1476-5810"},{"type":"electronic","value":"1476-5829"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}